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Sirt1 is anNAD1-dependent deacetylase that extends lifespan in lower organisms and improvesmetabolism
and delays the onset of age-related diseases inmammals. Herewe show that SRT1720, a synthetic compound
that was identified for its ability to activate Sirt1 in vitro, extends bothmean andmaximum lifespan of adult
mice fed a high-fat diet. This lifespan extension is accompanied by health benefits including reduced liver
steatosis, increased insulin sensitivity, enhanced locomotor activity and normalization of gene expression
profiles and markers of inflammation and apoptosis, all in the absence of any observable toxicity. Using a
conditional SIRT1 knockout mouse and specific gene knockdowns we show SRT1720 affects mitochondrial
respiration in a Sirt1- and PGC-1a-dependentmanner. These findings indicate that SRT1720 has long-term
benefits and demonstrate for the first time the feasibility of designing novel molecules that are safe and
effective in promoting longevity and preventing multiple age-related diseases in mammals.
A
s rates for obesity among humans continue to climb, both in the United States and worldwide, the global
burden of obesity-related health consequences on quality and length of life—and healthcare spending—
rises in lockstep. There is growing evidence that increased adiposity accelerates the aging process, prim-
arily by promoting inflammation1,2 but also by suppressing the expression of longevity genes3,4. One longevity
gene that is suppressed by excess calorie intake is Sirt1, the mammalian ortholog of the NAD1-dependent
deacetylase discovered by virtue of its ability to increase lifespan in lower organisms3,4. Activation of Sirt1 with
compounds such as resveratrol is believed to hold promise as a countermeasure for diseases accelerated by obesity
and aging in mammals5,6. Indeed, in a previous study we found treatment of mice with resveratrol resulted in
benefits to lifespan and healthspan (e.g. metabolic dysfunction and hepatic steatosis) in mice on a high-fat diet7,
consistent with later reports that mice with additional Sirt1 also show improvements inmeasures of healthspan8,9.
However, given that resveratrol has a number of in vivo targets10, the extent to which its effects are mediated by
Sirt1 is the subject of considerable debate.
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SRT1720, a compound that activates Sirt1 in vitro11, is one of a
series of pharmaceutical compounds that are being investigated for
their efficacy in the treatment of metabolic and chronic diseases
associated with aging. In short-term in vivo studies, SRT1720 has
been demonstrated to enhance insulin sensitivity and improve mea-
sures of mitochondrial capacity and oxidative metabolism in obese
rats and mice11213. However, the long-term effects of SRT1720, as
well as its ability to postpone diseases of aging, are currently
unknown. Moreover a recent report has raised questions about the
mechanism of action, metabolic effects and toxicity of SRT172014.
Both a recent in vitro study15 and this in vivo study comprehensively
address these issues by providing further data that SRT1720 benefits
multiple metabolic parameters, that Sirt1 is required for several of
these effects, and that the compound is well tolerated in mice even
when consumed daily in the diet over the greater part of the lifespan.
Indeed, SRT1720 treatment of mice fed a high-fat diet increased
lifespan in a dose-dependent manner. With regards to healthspan
SRT1720 promoted a gene expression profile similar to mice on a
lean diet while producing benefits tometabolism and organ structure
and function.
Results
SRT1720 extends lifespan and confers hepatic and pancreatic
protection in obese mice. To test the chronic effects of SRT1720
treatment we placed one-year old male C57BL/6J mice on a high-fat
diet (HFD) with two doses of SRT1720 and monitored them for the
remainder of their lifespan. As shown in Figure 1a, both mean and
maximum lifespan were extended by SRT1720 treatment (data on
dates of death for every mouse are included in Supplementary
Table 1). Survival among the high fat groups was significantly
different by the log-rank test (x2 5 70.4, P , 0.0001), with mice
fed a higher dose of SRT1720 (HFD-H; 100 mg/kg body weight)
living longer than their HFD counterparts. From birth, mean
lifespan extension from HFD in mice fed a lower dose of SRT1720
(HFD-L; 30 mg/kg) was 4% and HFD-H was 18%. From 56 weeks
of age (the age at which interventions were begun), mean lifespan
was increased 11% in HFD-L and 44% in HFD-H. Median lifespan
was 125 weeks for SD, 94 weeks for HFD, 103 weeks for HFD-L and
115 for HFD-H. Maximum lifespan (computed from the longest-
lived 10% per group) was significantly extended in the HFD-H
group (P 5 0.01) and the hazard ratio for death was significantly
reduced (x2 5 20.0, P , 0.0001, PHREG analysis of maximum
likelihood estimates). Extension of maximum lifespan from HFD
was 3% and 5% from birth and 6% and 9% from diet onset in the
HFD-L and HFD-H groups, respectively. Likewise, the high dose of
SRT1720 altered the hazard rate for mortality, shifting the curves
towards those of the SD and away from the HFD (Supplementary
Fig. 1).
Lifespan extension by SRT1720 occurred despite rapid and robust
weight gain by all HFD groups compared with SD controls, as is
apparent in the body weight curves over the course of the feeding
study (Fig. 1b). Importantly, while all HFD groups consumed sig-
nificantly more calories than the SD controls, there was no difference
among the HFD groups in calorie consumption (Fig. 1b and Supple-
mentary Fig. 1c). We also monitored SRT1720 levels in plasma at
120 weeks of age and, as expected, SRT1720 was undetectable in
plasma from SD controls and was found in the highest concentration
in plasma from the HFD-H mice (Supplementary Table 2).
Lifespan extension in the SRT1720-treated mice was accom-
panied by a profound reversal of the structural and functional deficits
induced by the high fat diet in liver (Fig. 1c) and pancreas (Fig. 1d). In
the liver (Fig. 1c) we observed a reduction in fat accumulation asso-
ciated with consumption of a high-fat diet at 82 weeks of age, which
was apparent even to the naked eye (note enlargement and pallid
color of HFD liver inset compared with SD and HFD-H). Histologi-
cal examination of liver sections stained with oil red O showed that
accumulation of lipid droplets in the livers of the HFD was more
pronounced than in the SD or HFD-H group, and blinded scoring
of the liver sections for steatosis on a scale of 0–4 (with 4 being the
most severe) confirmed that the HFD-H livers were significantly less
fatty than the HFD livers. These results corroborate data from a
severalmousemodels of obesity, all of which showed reduced hepatic
fat accumulation after SRT1720 treatment12,16,17. Giving further sup-
port to the involvement of Sirt1 in reduced steatosis, these results are
consistent with data from mice engineered with hepatocyte-specific
overexpression of Sirt118. Assessments of liver function via serum
levels of the transaminases alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), which are released into circula-
tion following hepatocellular damage, both indicate liver function is
compromised in HFD mice. Treatment with the high dose of
SRT1720 reduced both ALT andAST levels and the effect was greater
for AST which was normalized to SD levels by SRT1720.
Many patients with type 2 diabetes will eventually need insulin due
to the failure of pancreatic beta cells. Hence there is considerable
interest in finding agents that preserve beta cell function. Activators
of Sirt1 have not yet been examined in this regard. Staining of
pancreata from the mice revealed islet area was increased in mice
on the HFD but not in the HFD-H mice (Fig. 1d), indicating that
SRT1720 protects against islet hypertrophy, a hallmark of the insu-
lin resistance associated with obesity. Within islets, the percentage
of islet area represented by a cells was reduced in both the HFD
and HFD-H, although the reduction in the HFD-H was less than
that in the HFD. It is interesting to note that secretion of glucagon
during fasting is necessary to prevent neuroglycopenia, and, while
this has not been reported, our results suggest that animals fed a
high-fat diet have a reduced requirement for glucagon reflective of
chronic caloric abundance. Regarding insulin production, the frac-
tion of b cells present in the islets increased in the HFD, a common
consequence of weight gain and associated insulin resistance.
However, despite similar weight gain in the HFD-H animals, b cell
area was significantly less than in the HFD.
SRT1720 improves body composition, glucose homeostasis and
metabolism in mice on a high-fat diet. Gross changes to whole
organ weight were noted among the diet groups (Fig. 2a) and, as
anticipated, the reduced accumulation of fat in the livers of the
HFD-H mice correlated with a reduction in liver mass compared
with HFD mice assessed at 82 weeks of age. Livers from the HFD-
Lmice were also smaller than HFD livers, although both HFD-L and
HFD-H livers were still somewhat larger than SD livers.
Heart and kidney mass, however, were not increased at all in the
mice treated with SRT1720, only in untreated HFD mice. Assess-
ments of other major pathological changes to organs at 82 weeks of
age including heart, kidney, liver, spleen and lung are included in
Supplementary Table 3a, and did not reveal major differences among
the groups. No indication of toxicity by SRT1720 was noted in the
mice at sacrifice or in necropsies performed after death in the
remainder of the mice. Results from necropsies performed following
spontaneous death revealed 6% of mice in the HFD group showed
clear visual signs of ischemic foci in the heart (seen as pale areas of
the tissue) while only 1% of hearts from the SD and HFD-L groups
and none of the HFD-H indicated ischemia (Supplementary Table
3b). Further investigation of cardiac function by echocardiography
revealed no significant differences among the treatment groups at
118 weeks of age in either heart rate or ejection fraction (Supple-
mentary Fig. 3a,b). Presence of perirenal fat was only observed in the
HFD groups and was highest in the untreated HFD group at 5%
(Supplementary Table 3b). Visible hepatic steatosis at necropsy
was greatest in the HFD group (43%) and was reduced by the low
dose of SRT1720 (24%) and further by the high dose (11%), although
the lowest incidence was in the SD group (4%) in agreement with
the blinded pathological scoring results (Fig. 1c). These results are
www.nature.com/scientificreports
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consistent with the effects of resveratrol, which was also found to
reduce cardiovascular and liver pathologies in conjunction with
increased survival19.
Whole-body fat mass (Fig. 2b), assessed by nuclear magnetic
resonance (NMR) spectroscopy and presented as the average of
measurements collected longitudinally at 64, 80 and 94 weeks of
age, doubled in the HFD mice compared with SD and this increase
was significantly reduced by treatment with the high dose of
SRT1720. Serum high density lipoprotein (HDL), positively asso-
ciated with cardiovascular health, was increased in HFD-H above
all other diet groups, including SD (Fig. 2b). This effect occurred
despite an equivalent increase in total cholesterol in all high-fat
diets (Supplementary Fig. 3c). Because our current observations of
improved body composition and structural changes in liver and
pancreas with SRT1720 treatment suggest more efficient regulation
of glucose homeostasis, we quantified serum levels of glucose and
insulin in fasting mice (Fig. 2b). While circulating glucose was
unchanged by the high-fat diet, insulin levels were more than
doubled in the HFD compared with SD and HFD-H. In a similar
fashion elevation of the homeostasis model assessment (HOMA)
value (which evaluates insulin resistance) was blocked by treatment
with SRT1720 which is consistent with the observation that SRT1720
enhanced insulin sensitivity in mice infused with glucose under a
hyperinsulinemic-euglycemic clamp12.
Figure 1 | SRT1720 extends lifespan and reverses organ pathology associated with a high-fat diet. (a) Kaplan-Meier survival curves of mice fed a
standard diet (SD) or a high-fat diet (HFD) supplemented with SRT1720 at either a low (HFD-L) or high (HFD-H) dose.Mean andmaximum lifespan in
weeks and the hazard ratio for mortality are represented below. In the parentheses the increases in maximum lifespan from birth and then diet onset are
given. (b) Body weights of the groups over time, with average caloric intake over the course of the feeding study in the inset. Below are images of
representativemice to illustrate phenotypic bodymass of the groups at 82 weeks of age. (c) SRT1720maintained normal liver appearance and reduced the
onset of fatty liver as depicted by images of whole livers harvested after 12 weeks on diets and subsequent oil redO staining. Quantification of steatosis was
performed by a blinded pathologist on livers from 82 week-old mice (26 weeks on diets; n5 6). Serum levels of the aminotransferases ALT and AST were
reduced by SRT1720 compared with HFD (n 5 6; age 5 82 wks; diet 5 26 wks). (d) SRT1720 normalized pancreas morphology as illustrated by
immunostaining for glucagon-producing cells (a cells, green) and insulin-producing cells (b cells, red) in islets, and quantification of islet area and
relative a-cell and b-cell areas within the islets (n 5 8; diet 5 12 weeks). Data are represented as the mean 6 SEM. *P, 0.0083 from SD; {P, 0.0083
from HFD.
www.nature.com/scientificreports
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To further investigate the underlying effects involved in the
observed changes to lifespan and body composition we assessed
the metabolic and locomotor effects of SRT1720 in the mice at
122 weeks of age (Fig. 2c and 2d). The VO2 for all mice displayed
the expected diurnal rhythmof increasedVO2 during the dark period
(when mice are normally more active and feeding). The HFD mice,
however, had an increased VO2 compared with SD controls, which
was most apparent during the light cycle (Supplementary Fig. 4a).
Interestingly, SRT1720 reversed this trend in theHFD-L andHFD-H
groups. There was no change to VCO2 production or the respiratory
exchange ratio related to diet treatment (Supplementary Fig. 4b and
4c). Regarding locomotion, while there was no difference in total
X-axis activity (which includes grooming and feeding movements
performed in a stationary position), the HFD and HFD-L mice were
less ambulatory along the X axis than SD controls. All HFD groups
were less active vertically (on the Y axis) than SD controls. These
results were similar to those obtained using another test of locomotor
activity, the inclined screen test, wherein the HFD mice covered a
significantly shorter distance than the SD controls but the HFD-H
mice did not (Supplementary Fig. 4c).
SRT1720 suppresses hepatic apoptosis and normalizes gene
expression in obese mice. To more clearly determine the mole-
cular basis for the preservation of health and survival by SRT1720
in animals consuming a high-fat diet, we next examined its effects on
apoptotic markers and transcription in the liver. We found that
SRT1720 treatment blocked an increase in markers of apoptosis,
namely caspase 3 activity and DNA fragmentation, incurred by the
HFD relative to SD controls (Fig. 3a). Apoptotic cell death in the
hearts was likewise prevented by the drug treatment (Supplementary
Fig. 3d), corroborating observations of reduced apoptosis and
cleaved caspase 3 expression in mouse kidneys with ureteral obstruc-
tion treated with SRT172018. Assessment of global changes in gene
expression was performed using whole-genomemicroarray followed
by parametric analysis of geneset enrichment (PAGE) on the livers.
Similar to the effects of resveratrol7,21–24, SRT1720 induced a
Figure 2 | SRT1720 mitigates the negative physiological implications of a high-fat diet in mice. (a) Organ weights were significantly increased in the
HFDmice compared with SD and reduced by SRT1720 (n5 6; age 5 82 wks; diet 5 26 wks). (b) Fat mass increased in all high fat groups relative to SD,
however fat mass was significantly reduced in HFD-H compared with HFD (n5 15 at 64, 80 and 94 weeks of age). HDL cholesterol was increased in sera
from HFD-H mice (n 5 6; age 5 82 wks; diet 5 26 wks). While serum glucose was unchanged, serum insulin was increased in HFD but not in HFD-H
compared with SD. The HOMA calculation of insulin resistance was likewise increased in the HFD but not the SRT1720-treated group (n 5 8; age 5 40
weeks; diet 5 12 weeks). (c) Circadian rhythm of oxygen intake over 60 h is plotted without error bars for clarity (see Supplementary Fig. 4a for average
VO2 during light and dark cycles with SEM) (n 5 14 (SD), 12 (HFD), 10 (HFD-L), 14 (HFD-H); age 5 122 wks; diet 5 66 wks). (d) Daily locomotor
activity represented as total movement along the horizontal plane (X Total), ambulatory movement along the horizontal plane (X Amb) and movement
across the vertical axis (Z). Ambulatory and verticalmovementwas reduced in theHFD groups comparedwith SD, and the high dose of SRT1720 reversed
this effect in ambulatorymovement (n5 14 (SD), 12 (HFD), 10 (HFD-L), 14 (HFD-H); age5 122 wks; diet5 66 wks). Data are represented as themean
6 SEM. *P , 0.0083 from SD; {P , 0.0083 from HFD.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 70 | DOI: 10.1038/srep00070 4
profound shift away from expression patterns induced by a high-fat
diet. Of the pathways that were significantly changed by the high-fat
diet, the low and high doses of SRT1720 induced opposing effects
in 92.6% and 89.1% of cases, respectively (Fig. 3b). In particular,
SRT1720 treatment suppressed genes in the liver that have pre-
viously been shown to correlate with aging in studies on kidney
and brain, and decreased expression of several gene sets associated
with inflammatory changes (Supplementary Table 4a). A subset of
expression changes was verified by polymerase chain reaction with
reverse transcription (RT-qPCR) (Supplementary Table 4b,c).
The most highly affected transcripts are presented in Figure 3c,
and the complete data set is available at http://www.ncbi.nlm.nih.
gov/geo, accession number GSE19102. Intriguingly, this short list
includes Hes1, a known interacting partner of Sirt125, as well as
Gadd45, a DNA repair factor that has been shown to be regulated
via Sirt1-dependent deacetylation of FOXO transcription factors26.
It also includes Plk3, which is at least partially under the control of
NFkB, and might have been expected to decrease, rather than
increase, due to the inhibitory effect of Sirt1 on NFkB transactiva-
tion.We therefore attempted to ask whether our transcriptional data
more broadly support the activation of Sirt1 by SRT1720. Unfortun-
ately, this is a very difficult question to address at present, since
microarray results are not available from mice overexpressing Sirt1,
and post-translational modifications induced by Sirt1 are far better
characterized than are the resulting transcriptional consequences.
A small set of transcriptional changes suggestive of increased glu-
coneogenesis and adiponectin signaling, decreased inflammation,
and alterations in antioxidant defenses and lipid metabolism have
been identified in the livers of mice with enhanced SIRT1 activity
(two BAC-transgenic strains8,9) and another strain lacking the Sirt1
inhibitory protein DBC127. Of these 12 genes, 9 were represented on
our arrays, and 4 were changed to a statistically significant degree
(P, 0.05), 3 in the predicted direction and one in the opposite, albeit
with relatively small absolute effects (Supplementary Table 4d).
Therefore, these results are not conclusive, but do provide suggestive
evidence for an increase in gluconeogenesis (increased expression of
glucose-6-phosphatase and IGFBP1) and adiponectin signaling
(upregulation of adiponectin receptor 2) following treatment with
SRT1720. The most likely reason we did not detect a more compel-
ling overlap with prior studies is because our mice were sacrificed in
the fed state, when gluconeogenesis is normally suppressed, whereas
prior studies were performed in fasted animals or in isolated, stimu-
lated hepatocytes. Because neither of the inflammatory markers that
were suppressed by SIRT1, tumor necrosis factor (TNF) and inter-
leukin-6 (IL-6), passed the quality control analysis on our arrays, we
assayed these transcripts by RT-PCR. We found a dose-dependent
suppression of both genes by SRT1720 (Fig. 3d), indicating that this
compound and SIRT1 have similar anti-inflammatory effects.
Because we noted a number of transcriptional changes in the
PAGE analysis that might be considered pro-inflammatory (for
example, a small increase in NFkB-related genes), we also sought
to directly test the effect of SRT1720 on additional markers of inflam-
mation in the high fat groups. We found that expression of inter-
leukin 1b (IL-1b), and inducible nitric oxide synthase (iNOS), like
TNF and IL-6, were elevated by the HFD relative to SD, and that
both doses of SRT1720 tended to suppress these inflammatory
changes in both liver and heart, although the effects were not signifi-
cant in all cases (Fig. 3d and Supplementary Fig. 3e). Circulating
levels of IL-6 in the serum of the HFD mice were also reduced by
SRT1720 (Supplementary Table 4e). In support of the conclusion
Figure 3 | SRT1720 suppresses apoptosis and restores a more normal gene expression profile indicative of reduced inflammation in the livers of mice
fed a high-fat diet. (a) Two indicators of increased programmed cell death, caspase 3 activity and DNA fragmentation, were increased in the HFD
comparedwith SD. This effect was completely blocked by both doses of SRT1720 (n5 6; age5 82 wks; diet5 26 wks). (b) Parametric analysis of gene-set
enrichment (PAGE) comparing every pathway significantly upregulated (red) or downregulated (blue) by HFD (as compared with SD, 349 pathways of
1687 considered), and the corresponding effects of the low and high doses of SRT1720 on those same pathways (n 5 3; age 5 82 wks; diet 5 26 wks). (c)
The five most highly upregulated and downregulated named genes, based on fold-change in HFD-R compared to HFD (filtering on a false discovery rate
of,0.05). (d) Multiple pro-inflammatory markers including TNF, IL-6, IL-1b and iNOS were increased in the HFD mice relative to SD. No significant
increase from SDwas seen in theHFD-H group, and there was a significant decrease fromHFD in the TNF and iNOS expression of theHFD-H livers (n5
6; age 5 82 wks; diet 5 26 wks). *P , 0.0083 from SD; {P , 0.0083 from HFD.
www.nature.com/scientificreports
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that SRT1720 reduces inflammation, accumulation of isoprostanes
(indicative of lipid peroxidation and oxidative stress) was increased
by the high-fat diet but kept at SD levels by both doses of the drug
(Supplementary Fig. 3f).
Since both resveratrol and SRT1720 have been proposed to work
through a common target—Sirt1—we tested whether the transcrip-
tional signatures induced by these two treatments showed overlap-
ping effects. Indeed, we observed a statistically significant correlation
between the effects of resveratrol and SRT1720 (Supplementary
Fig. 5). Specific transcripts that are regulated in common have been
tabulated in Supplementary Table 4f. These include a number of
genes that encode cytochrome P-450 enzymes, which are known to
be altered in long-lived dwarf mice as well as by calorie restriction28.
Additionally, SRT1720 decreased expression of complement com-
ponent 1q, which has emerged as a robust expression biomarker of
aging that, in cerebellum, is both increased with age and suppressed
by calorie restriction22.
PGC-1a hepatic acetylation levels are preserved and mitochondr-
ial biogenesis is increased by SRT1720.To confirm the activation of
Sirt1 by SRT1720 in vivo we analyzed the acetylation levels of PGC-
1a, a direct target of Sirt1, in the liver of 40 week old mice treated on
diets for 12 weeks. The HFD group showed a dramatic increase in
PGC-1a acetylation in the liver compared with SD controls (Fig. 4a).
Induction of PGC-1 a acetylation by high-fat intake has been
reported in muscle29. Treatment with SRT1720 attenuated this
effect (Fig. 4a), which is consistent with a previous report where
SRT1720 decreased relative PGC-1a acetylation12. In contrast to
the liver, PGC-1a acetylation was not reduced by SRT1720 treat-
ment in the muscle (Supplementary Fig. 6a). We further found
that SRT1720 promoted the deacetylation of two different Sirt1
substrates, p53 and histone H4, at low micromolar concentrations
in vitro (Supplementary Fig. 6b,c).
To more closely assess the role of Sirt1 in mediating SRT1720’s
effects in vitro we employed mouse embryonic fibroblasts (MEFs)
that were derived from either SIRT1 knockout (KO) or wild type
mice (WT). Given that previously we have shown that Sirt1 activa-
tion improves mitochondrial function7,30, in the current study we
assessed the ability of SRT1720 to increase the capacity formitochon-
drial respiration in the MEFs. Oxygen consumption during carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)-uncoupled
respiration was compared with basal respiration with or without
treatment with 1 mM SRT1720. SRT1720-treated WTMEFs showed
a significant increase in their capacity for O2 intake while KO MEFs
did not, suggesting Sirt1 is required for SRT1720-driven increases
to mitochondrial biogenesis (Fig. 4b). The current results agree
with previous reports in which both Sirt1 overexpression and
resveratrol treatment have been shown to increase mitochondrial
biogenesis7,30,31, and a recent report showing increasedmitochondrial
biogenesis in cultured renal proximal tubular cells treated with
SRT172032. While these data indicate the SRT1720-treated WT
MEFs had an increased capacity for respiration, this does not neces-
sarily translate to increased basal metabolism, as both the MEFs
(Supplementary Fig. 6d) and the mice (Fig. 2c) exhibited normal
or decreased O2 intake under basal conditions. This agrees with data
collected under calorie restriction, which either lowers33 or does not
affect skeletal muscle mitochondrial oxygen consumption34. These
observations hint at the possibility that Sirt1 activation by calorie
restriction or resveratrol may induce the proliferation of mitochon-
dria with efficient electron transport systems resulting in lower
whole-body oxygen consumption.
We also assessed the Sirt1-dependence of increased stress
resistance by SRT1720 (Fig. 4c). WT MEFs that were primed by
incubation with SRT1720 at 1 or 3 mM showed increased survival
compared with untreated controls when treated with 500 mMH2O2
for 24 h while MEFs from KO mice, in contrast, did not. This Sirt1
dependence may relate to Sirt1’s action on p53, as we also observed
increased deacetylation of p53 in the WT MEFs as compared to the
KO MEFs (Supplementary Fig. 6e).
To better understand the involvement of PGC-1a in SRT1720’s
effects on cellular metabolism we employed HepG2 cells transfected
with siRNA that was either non-targeting or was specific for PGC-1a
1 and 2 (Supplementary Figure 7). SRT1720 treatment resulted in
increased mitochondrial membrane potential (Fig. 4d) and cellular
ATP content (Fig. 4e) in non-targeting siRNA transfected cells and
this effect was blocked by PGC-1a knockdown.
Mitochondrial respiratory capacity is not affected by SRT1720 in
Sirt1 knockout mice. To further explore the Sirt1-dependency of
SRT1720’s effects on respiration we generated a conditional Sirt1
knockout mouse to measure oxygen consumption in mitochondria
isolated from the liver. Oxygen consumption during state 3 respira-
tion was suppressed by HFD and maintained by SRT1720 treatment
in wild type mice but not in the Sirt1 knockouts (Fig. 5a). State 4
respiration was not affected by Sirt1 knockout, HFD or SRT1720
treatment (Fig. 5b). Both the respiratory control ratio (RCR; state
3/state 4) (Fig. 5c) and FCCP-induced respiration (Fig. 5d) were
reduced by HFD and oxidative capacity was only rescued by
SRT1720 treatment in mitochondria from wild type mice and not
in knockout mice, demonstrating that the ability of SRT1720 to
increase respiration is Sirt1-dependent in vitro and in vivo.
Discussion
The current study shows that SRT1720, a member of a class of drugs
that are in vitro Sirt1-activators, has a number of long-term benefits
in mice that include shifting physiological parameters in mice con-
suming a high-fat diet towards those consuming a standard diet,
modulating gene expression pathways associated with longevity,
and improving overall health. These effects led to improvements in
a variety of measures including survival, motor function, insulin
sensitivity, organ pathology, and metabolic activity. With regards
to energy metabolism, SRT1720 improved insulin sensitivity, main-
tained liver and pancreatic function, and prevented several metabo-
lic changes associated with a high-fat diet. At the molecular level,
SRT1720 reversed the gene expression profile induced by the high-
fat diet with regards to markers of inflammation, apoptosis and
oxidative stress. In vivo, SRT1720 promoted the deacetylation of
hepatic PGC-1a, a known Sirt1 target that regulates mitochondrial
biogenesis, stress resistance and survival35. In vitro, SRT1720-driven
increases in cell survival and mitochondrial respiration were also
Sirt1-dependent. While both mean and maximum lifespans were
significantly extended in the mice, mean lifespan extension through
reduction of premature death and increased healthspan was themost
overt benefit of SRT1720 treatment. This is in agreement with a
recent report where transgenic mice overexpressing Sirt1 displayed
increased glucose tolerance and reduced susceptibility to induced
tumors but not increased survival when fed a standard diet36. In
the case of our mice, which were subjected to metabolic stress by
the high fat diet, SRT1720 was able to dramatically shift the lifespan
curves towards a more rectangular shape by acting to prevent
premature death.
Our results continue to support the beneficial pharmacological
effect of SRT1720 in models of metabolic disease despite a recent
report by Pacholec and colleagues to the contrary14 where the authors
report 100 mg/kg SRT1720 is not tolerable and increases mortality
in mice and that the compound does not elicit beneficial effects in
the Lepob/ob mouse model of diabetes. This conclusion is inconsistent
with not only our findings but also several additional studies where
SRT1720 has been reported to exert positive effects in multiple mod-
els of metabolic disease including Lepob/ob mice11, diet-induced obese
mice11,12, MSG-induced hypothalamic obese mice15 and Zucker fa/fa
rats11,13. Pacholec and colleagues did report that fasting insulin levels
www.nature.com/scientificreports
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are reduced by SRT1720 administration14, which is in agreement
with our findings (Fig. 2) and with data reported previously in
diet-induced obese mice11. The putative toxicity of SRT1720 admi-
nistered at a 100 mg/kg oral dose to 8 mice over 18 days14 is incon-
sistent with a study where the compound exhibited no toxicity at
a 5-fold higher dose for 15 weeks12 nor is it consistent with our
long-term feeding study involving over 100 mice consuming an
equivalent daily dose. In fact, our mice showed increased survival
and improvement in multiple physiological parameters in response
to SRT1720 treatment and did not display overt signs of toxicity even
after more than 80 weeks of treatment.
There is also ongoing debate as to whether SRT1720 and resver-
atrol are direct activators of Sirt111,14,15,37–39. The data cited in argu-
ment against direct activation by these compounds are derived from
Figure 4 | SRT1720 reduces PGC-1a acetylation in the liver in vivo and increases cell survival and respiration in vitro. (a) Relative PGC-1a acetylation
was analyzed by immunoprecipitation from nuclear extracts from the liver followed by an immunoblot against acetylated lysine residues (n5 8; age5 40
weeks; diet5 12 weeks). Data are represented as themean6 SEM. *P, 0.0083 from SD. (b) Oxygen consumption in stimulated, respiration-uncoupled
MEFs is expressed as the percent increase over basal respiration. Compared with vehicle-treated cells, only WTMEFs displayed increased capacity for O2
consumption. *P , 0.05 from 0 mM. (c) Cell survival following oxidative stress by 24 h exposure to H2O2 (500 mM) showed increased survival after
pretreatment with SRT1720 was confined to theWTMEFs. (d) Increases tomitochondrial membrane potential in HepG2 cells only occurred in cells that
were transfected with non-targeting siRNA, and this effect was blocked by siRNAs that targeted PGC-1a 1 and 2. (e) Concurrently an increase in cellular
ATP content was dependent on PGC-1a. Data are represented as the mean 6 SEM. *P , 0.0083 from 0 mM.
www.nature.com/scientificreports
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biochemical assays that are poorly understood in terms of how well
they model the cellular and in vivo settings in which beneficial effects
have been demonstrated, including those in our current study
(Fig. 4, Supplementary Fig. 10,12) and in previous studies12,13,16,40–42.
Furthermore, SRT1720 and resveratrol have been shown to induce
parallel transcriptional changes to mouse liver gene expression both
here (Supplementary Fig. 5) and elsewhere21. The transcriptional
and physiological correlations and the Sirt1-dependence both in
vitro and in vivo suggest a common mechanism. At present the
simplest explanation is that the target is Sirt1, which agrees with
multiple cellular assays demonstrating Sirt1-dependency reported
here (Fig. 4, Supplementary Fig. 10,12) and elsewhere12,13,16,40–42. It
should be noted, however, that the present in vivo effects by SRT1720
on healthspan or lifespan do not distinguish between direct and
indirect Sirt1 activation. What our data show conclusively is that
long-term treatment of obese mice with SRT1720 allows them to live
healthier, more vigorous lives and the noteworthy significance of
these findings is that potent molecules may one day be developed
at the bench and translated to clinical practice for the promotion of
healthspan and lifespan in humans.
Methods
Animals and diets.Male C57BL/6J mice were obtained from the Jackson Laboratory
(Bar Harbor, ME) at 15 weeks of age and held at the Holabird NIA/NIH research
facility in Baltimore, MD. During the initial holding period the mice were housed in
groups of 4 with ad libitum access to a standard chow diet (2018 Teklad Global 18%
Protein Rodent Diet, Harlan Teklad, Madison, WI) and tap water until 52 weeks of
age at which time the mice were separated into groups of 3. Random cages with in
each group were designated for different experimental procedures (e.g. NMR) from
which to select mice as needed throughout the study. At 56 weeks the mice were
randomized into four diet groups of 108 mice each after which the mice were fed
either a standard AIN-93G diet (SD; carbohydrate:protein:fat ratio of 64:19:17
percent of kcal) or a high fat diet consisting of AIN-93G modified to provide 60% of
calories from fat (HFD; carbohydrate:protein:fat ratio of 16:23:61). SRT1720 was
added to theHFD at a low dose (0.6 g/kg, HFD-L) and a high dose (2.0 g/kg, HFD-H)
that were formulated to provide daily doses of approximately 30 mg/kg and
100 mg/kg, respectively, to themice. The study diets were purchased fromDyets, Inc.
(Bethlehem, PA) and SRT1720 was provided by Sirtris Pharmaceuticals, Inc.
(Cambridge, MA). Throughout the duration of the study all groups had ad libitum
access to weighed amounts of their prescribed diet and water with body weight and
food intake monitored twice monthly.
Because the Holabird facility was discontinued for use by the NIA in October of
2008, the mice were moved to the Gerontology Research Center of the NIA, also in
Baltimore, MD, at 111 weeks of age. Both facility animal rooms were maintained at
20–22uCwith 30–70% relative humidity and a 12 hour light/dark cycle. No significant
Figure 5 | SRT1720 rescues respiratory capacity inmitochondria fromwild typemice treated with a high fat diet but not after Sirt1 knockout. (a) State
3 oxygen consumption by mitochondria isolated from the liver was reduced by HFD. Treatment with SRT1720 in the HFD was protective only in WT
mice. (b) Oxygen consumption during state 4 respiration was unchanged by diet or genetic manipulation. (c) The respiratory control ratio was also
reduced by HFD and rescued by SRT1720 only in WT mice, as was FCCP-induced respiration (d). n 5 4 mice per group; age 5 30–32 weeks; diet 5 18
weeks. Data are represented as the mean 6 SEM. *P , 0.05 from WT SD, #P , 0.05 from KO SD, &P , 0.05 from WT HFD.
www.nature.com/scientificreports
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alteration to body weight, food intake or survival was noted in the two weeks after the
move. All animal protocols were approved by the Gerontology Research Center
Animal Care and Use Committee (352-LEG-2009) of the National Institute on Aging
and by the Harvard Medical School Standard Committee on Animals.
Survival study. Animals were inspected daily for health issues and deaths were
recorded for each animal. Moribund animals were euthanized by CO2 asphyxiation
and recorded. Every animal found dead or euthanized was necropsied. Criteria for
euthanasia were based on an independent assessment by a veterinarian according to
AAALAC guidelines and only cases where the condition of the animal was considered
incompatible with continued survival are represented as deaths in the curves. Animals
removed at sacrifice were considered as censored deaths.
Histology. The mice were fasted overnight. Following euthanasia, organs were
excised and either frozen in liquid nitrogen or fixed in 4% paraformaldehyde. Oil red
O staining on frozen liver was performed by Histoserv Inc. (Germantown, MD) and
fixed tissues were stained with hematoxylin and eosin and then scored blindly for
overall pathology.
Serummarkers and HOMA calculation. Plasma concentrations of ALT, AST, HDL
and total cholesterol were measured using the Cobas Integra 400 automated analyzer
(Roche Diagnostics, Basel, Switzerland). Glucose was measured in whole blood using
the Ascensia Elite glucose meter (Bayer, Mishawaka, IN). For insulin measurements,
whole blood was allowed to clot for 30 min and spun at 14,000 rpm in a benchtop
centrifuge for 7 min to pellet blood cells after which the serum was transferred to a
fresh tube and stored at 280uC. The hormones were then measured by enzyme-
linked immunosorbent assay (ELISA, Crystal Chem Inc., Downers Grove, IL)
according to the kit manufacturers’ instructions. Insulin resistance was calculated
from fasted glucose and insulin values using the HOMA2 Calculator software
available from the Oxford Centre for Diabetes, Endocrinology and Metabolism,
Diabetes Trials Unit website (www.dtu.ox.ac.uk).
Pancreatic islet immunofluorescence and quantification. Mouse pancreata were
fixed in 4% paraformaldehyde, embedded in OCT compound (Tissue-Tek; Electron
Microscopy Sciences, Hatfield, PA), frozen, and stored at 280uC. Tissues were then
cut with a cryostat to yield sections 7–10 mm thick. Antigen retrieval (Biogenex, San
Ramon, CA) was used on all sections. Slides were mounted using PermaFluor
(Thermo Scientific, Waltham, MA) and Nuclei were labeled with TOPRO-3
(Molecular Probes, Carlsbad, CA). Tissue was incubated with primary insulin and
glucagon antibodies and secondary antibodies for pancreatic immunofluorescence
from the Jackson ImmunoResearch Lab (West Grove, PA). Images were captured
using a Zeiss LSM 410 confocal microscope.
Body composition.Measurements of lean, fat and fluidmass in whole, livemice were
acquired by nuclear magnetic resonance (NMR) using the Minispec LF90 (Bruker
Optics, Billerica, MA).
Echocardiography. Detailed methods are included in the Supplementary
Information.
Metabolic and physical activity. Detailed methods are included in the
Supplementary Information.
Inclined screen. Detailed methods are included in the Supplementary Information.
Quantitative real-time PCR. Detailed methods are included in the Supplementary
Information.
Apoptosis and isoprostanes. Detailed methods are included in the Supplementary
Information.
Microarray. Detailed methods are included in the Supplementary Information.
PGC-1a deacetylation. PGC-1a deacetylation was evaluated by immunoprecipitating
500–1000 mg of total proteins from liver or muscle with PGC-1a antibody, followed
by immunoblotting against acetylated lysine or against PGC-1a. All antibodies were
fromCell Signaling (Cell Signaling Technology, Inc., Danvers, MA), and detection was
performed using ultrasensitive horseradish peroxidase chemiluminescence (Pierce
Protein Research Products, a division of Thermo Fisher Scientific Inc., Rockford, IL).
Cell culture, survival andmitochondrial biogenesis.Detailedmethods are included
in the Supplementary Information.
Oxygen consumption. Oxygen consumption in Sirt1 WT and KO MEFs was
measured using the Seahorse 24XF instrument (Seahorse Biosciences, North Billerica,
MA) according to company protocols. Cells were seeded into a seahorse tissue culture
plate at a density of 40,000 cells per well and 16 h after seeding either 0.025% DMSO
or 1 mM SRT1720 was added to the wells. 24 h later media was changed to un-
buffered XF assay media at pH 7.4 (Seahorse Biosciences, North Billerica, MA)
supplemented with 25 mM glucose (Sigma-Aldrich, St. Louis, MO) and 1 mM
sodium-pyruvate and 1 mM glutamax (Invitrogen, Carlsbad, CA). Cells were
incubated for 1 h at 37uC at ambientO2 andCO2 concentration beforemeasurements
were taken. Respirationwasmeasured in 4 blocks of 3 times 3 minutes. The first block
measured the basal respiration rate. Next 1 mM oligomycin (EMD chemicals,
Gibbstown, NJ) was added to inhibit complex V and the second block was measured.
Then 0.3 mM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)
(Sigma-Aldrich, St. Louis,MO)was added to uncouple respiration and the third block
was measured. Finally 2 mM antimycin A (Sigma-Aldrich, St. Louis, MO) was added
to inhibit complex 3 and the last measurements were performed. Immediately after
finishing the measurements cells were counted using a Beckman Z1 Coulter counter
(Beckman Coulter Inc., Brea, CA).
In vitro Sirt1 deacetylase activity. Detailed methods are included in the
Supplementary Information.
Western blotting and p53 deacetylation. Detailed methods are included in the
Supplementary Information.
Mitochondrial function in HepG2 cells. The hepatoma-derived HepG2 cell line
(ATCC) was cultured in low glucose Dulbecco’s modified eagle medium (DMEM)
supplemented with 10% FBS and antibiotics (Invitrogen). Cells were maintained at
37uC in 5% CO2. For PGC-1a knockdown experiments, cells were transfected with
30 nM siRNA or a non-targeting siRNA (Invitrogen) using Lipofectamin 2000
(Invitrogen). Cells were treated with vehicle (0.001% DMSO) or SRT1720 (final
concentration of 1 mM in 0.001% DMSO) for 24 h. Mitochondrial membrane
potential was measured using tetramethylrhodamine methyl ester (TMRM) (Sigma)
as previously described43. ATP content wasmeasured using a commercial available kit
according to manufacturer’s instructions (Roche).
Sirt1 knockout experiments. Sirt1 was knocked out in adult animals using a
tamoxifen-inducible whole-body Cre-loxP system based on the floxed Exon4 SIRT1
knockout mouse44. Knockout in liver in this model is .85% based on Western
blotting for Sirt1. At 12–14 weeks of age mice were placed on either HFD or HFD 1
SRT1720 (2g/kg in food) for 18 weeks. Mitochondria were isolated from the liver of
malemice by conventionalmethods45 with slightmodifications46. Protein content was
determined by the biuret method47 calibrated with bovine serum albumin. Oxygen
consumption of mitochondria isolated from liver was polarographically
determinated with a Clark type polarographic oxygen48 with a PC-operated electrode
control unit (Oxygraph, Hansatech Instruments Ltd.). Mitochondria (1 mg) were
suspended under constant stirring at 25uC, in 1.4 ml of standard respiratory medium
(130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 5 mM KH2PO4, 50 mM EDTA, and
5 mM HEPES (pH 7.4) and 3 mM rotenone) and energized by adding succinate to a
final concentration of 5 mM. State 3 respiration was induced by adding 200 nmol
adenosine diphosphate (ADP). Oxygen consumption was also measured in the
presence of 1 mM carbonylcyanide-p-trifluoromethoxyphenylhydrazon (FCCP).
Statistics.Data are expressed as means 6 standard error of the mean (SEM). Single-
factor analyses of variance followed by Bonferroni-Dunn post-hoc tests were used for
all comparisons.Mortality during the survival study was assessed by using the logrank
test to compare the Kaplan-Meier survival curves. We compared Kaplan-Meier
survival estimates among the high fat diet groups with both log-rank tests and
Wilcoxon tests (SAS PROC LIFETEST). Results of both tests were consistent, so we
report only the P values given by the log-rank tests. The Cox proportional hazards
procedure was also used (SAS PROC PHREG). Of the 108 initial HFD mice 7 were
experimental, censored deaths (1 died at 71 weeks of age due to accidental drowning
by pulmonary gavage during an OGTT and 6 were culled during the sacrifice at 82
weeks of age). Of the 108 initial HFD-L mice 7 mice were experimental, censored
deaths (1 died at 71 weeks of age due to accidental drowning by pulmonary gavage
during an OGTT and 6 were culled during the sacrifice at 82 weeks of age). Of the 108
initial HFD-Hmice 7 mice were experimental, censored deaths (1 died at 71 weeks of
age due to accidental drowning by pulmonary gavage during an OGTT and 6 were
culled during the sacrifice at 82 weeks of age).
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